The KEYNOTE-177 phase 3 trial aimed to evaluate the cost-effectiveness of pembrolizumab from the payer’s perspective. Despite treatment variations, the results revealed pembrolizumab’s cost-effectiveness over chemotherapy at a 15 million/QALY threshold. Pembrolizumab significantly prolonged progression-free survival compared to chemotherapy for patients with advanced colorectal cancer with MSI-High or dMMR. Taniguchi S and the […]...